inclusion criteria: 1. age 18 to 74 years (at the time of informed consent) 2. male or female 3. patients who meet all of the following three criteria at the time of enrolment: 1. sars-cov-2-positive patients as measured by rtpcr by nasopharyngeal sampling 2. moderate patients with radiological evidence of pneumonia in the lung at the time of enrolment (rtg, ct, or uh), clearly described by the radiologist following the imaging examination. (the diagnosis of the finding should clearly include the presence of pneumonia to any extent, localization, and extent) 3. body temperature 37,5°c or more 4. patient requires hospitalization during the treatment period (obligation to stay in the hospital for whole treatment period, 14 days) 4. for premenopausal females, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug 5. signed informed consent by the patient or by the legal representative -

inclusion criteria: 1. age 18 to 74 years (at the time of informed consent) 2. male or female 3. patients who meet all of the following three criteria at the time of enrolment: 1. sars-cov-2-positive patients as measured by rtpcr by nasopharyngeal sampling 2. moderate patients with radiological evidence of pneumonia in the lung at the time of enrolment (rtg, ct, or uh), clearly described by the radiologist following the imaging examination. (the diagnosis of the finding should clearly include the presence of pneumonia to any extent, localization, and extent) 3. body temperature 37,5°c or more 4. patient requires hospitalization during the treatment period (obligation to stay in the hospital for whole treatment period, 14 days) 4. for premenopausal females, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug 5. signed informed consent by the patient or by the legal representative -

inclusion criteria: age 18 to 74 years (at the time of informed consent) male or female patients who meet all of the following three criteria at the time of enrolment: sars-cov-2-positive patients as measured by rtpcr by nasopharyngeal sampling moderate patients with radiological evidence of pneumonia in the lung at the time of enrolment (rtg, ct, or uh), clearly described by the radiologist following the imaging examination. (the diagnosis of the finding should clearly include the presence of pneumonia to any extent, localization, and extent) body temperature 37,5°c or more patient requires hospitalization during the treatment period (obligation to stay in the hospital for whole treatment period, 14 days) for premenopausal females, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug signed informed consent by the patient or by the legal representative -

inclusion criteria: age 18 to 74 years (at the time of informed consent) male or female patients who meet all of the following three criteria at the time of enrolment: sars-cov-2-positive patients as measured by rtpcr by nasopharyngeal sampling moderate patients with radiological evidence of pneumonia in the lung at the time of enrolment (rtg, ct, or uh), clearly described by the radiologist following the imaging examination. (the diagnosis of the finding should clearly include the presence of pneumonia to any extent, localization, and extent) body temperature 37,5°c or more patient requires hospitalization during the treatment period (obligation to stay in the hospital for whole treatment period, 14 days) for premenopausal females, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug signed informed consent by the patient or by the legal representative -

inclusion criteria: 1. age 18 to 74 years (at the time of informed consent) 2. male or female 3. patients who meet all of the following three criteria at the time of enrolment: 1. sars-cov-2-positive patients as measured by rtpcr by nasopharyngeal sampling 2. moderate patients with radiological evidence of pneumonia in the lung at the time of enrolment (rtg, ct, or uh), clearly described by the radiologist following the imaging examination. (the diagnosis of the finding should clearly include the presence of pneumonia to any extent, localization, and extent) 3. body temperature 37,5°c or more 4. patient requires hospitalization during the treatment period (obligation to stay in the hospital for whole treatment period, 14 days) 4. for premenopausal females, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug 5. signed informed consent by the patient or by the legal representative -

inclusion criteria: 1. age 18 to 74 years (at the time of informed consent) 2. male or female 3. patients who meet all of the following three criteria at the time of enrolment: 1. sars-cov-2-positive patients as measured by rtpcr by nasopharyngeal sampling 2. moderate patients with radiological evidence of pneumonia in the lung at the time of enrolment (rtg, ct, or uh), clearly described by the radiologist following the imaging examination. (the diagnosis of the finding should clearly include the presence of pneumonia to any extent, localization, and extent) 3. body temperature 37,5°c or more 4. patient requires hospitalization during the treatment period (obligation to stay in the hospital for whole treatment period, 14 days) 4. for premenopausal females, patients who have been confirmed to be negative on a pregnancy test before administration of the study drug 5. signed informed consent by the patient or by the legal representative -